Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
Rotate
<< Previous | New Search | Return to Search Results | Next >>

Jacob Rotmensch, MD

Jacob Rotmensch, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
  • Gynecologic Oncology
  • Obstetrics and Gynecology
Board Certification:
  • Gynecologic Oncology
  • Obstetrics & Gynecology
Faculty Rank: Professor
Medical or Graduate Education: Meharry Medical College School of Medicine
Residency: Johns Hopkins Hospital - Obstetrics and Gynecology
Fellowship: Johns Hopkins Hospital - Gynecologic Oncology
Clinical Expertise:
  • Cervical cancer
  • Endometrial cancer
  • Gynecologic cancer
  • Ovarian cancer
  • Uterine cancer
Research Interests:
  • Novel radioisotopes for the treatment of ovarian carcinoma
Google Map
  • University Gynecologic Oncology Associates
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 1010
  • Chicago, IL  60612
  • Phone: (312) 942-6300
  • Fax: (312) 942-6301
  • View Larger MapDriving Directions
Google Map
Google Map
Google Map
Google Map
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Immunohistochemical characterization of squamous differentiation and morular metaplasia in uterine endometrioid adenocarcinoma.
    Blanco LZ Jr, Heagley DE, Lee JC, Gown AM, Gattuso P, Rotmensch J, Guirguis A, Dewdney S, Bitterman P.
    Int J Gynecol Pathol. 2013
    2013 May
    32(3):283-92. doi: 10.1097/PGP.0b013e31826129e1.
  2. Use of cervical mucus to screen for gynecological malignancies: a pilot study.
    Lamzabi I, Buckingham L, Gebrekiristos M, Jain R, Gattuso P, Reddy V, Guirguis A, Dewdney S, Rotmensch J, Bitterman P.
    Mod Pathol. 2013
    2013 Jun 14. doi: 10.1038/modpathol.2013.92. [Epub ahead of print]
  3. Structural and mechanical profiles of native collagen fibers in vaginal wall connective tissues.
    Sridharan I, Ma Y, Kim T, Kobak W, Rotmensch J, Wang R.
    Biomaterials.
    2012 Feb
    33(5):1520-7
  4. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer.
    Yellapa A, Bahr JM, Bitterman P, Abramowicz JS, Edassery SL, Penumatsa K, Basu S, Rotmensch J, Barua A.
    Int J Gynecol Cancer. 2012
    2012 Feb
    22(2):199-207. doi: 10.1097/IGC.0b013e318236a27b.
  5. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study.
    Alvarez EA, Brady WE, Walker J, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn D, Harrison CR, Moore KN, Aghajanian C.
    Gynecol Oncol. 2012
    2012 Dec 20. doi:pii: S0090-8258(12)00970-5. 10.1016/j.ygyno.2012.12.022. [Epub ahead of print]
  6. Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.
    Barua A, Yellapa A, Bahr JM, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Bitterman P.
    Transl Oncol. 2012
    2012 Aug
    5(4):260-8. Epub 2012 Aug 1.
  7. Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.
    Khan MF, Bahr JM, Yellapa A, Bitterman P, Abramowicz JS, Edassery SL, Basu S, Rotmensch J, Barua A.
    Transl Oncol. 2012
    2012 Apr
    5(2):85-91. Epub 2012 Apr 1.
  8. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
    Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J, Maker AV, Prabhakar BS.
    Am J Obstet Gynecol.
    2011 May 27
  9. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
    Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL
    Gynecol Oncol
    2011 Mar
    120(3):459-63
  10. Optimal surgical debulking in uterine papillary serous carcinoma affects survival.
    Patsavas K, Woessner J, Gielda B, Rotmensch J, Yordan E, Bitterman P, Guirguis A.
    Gynecol Oncol.
    2011 Jun 1
    121(3):581-5
  11. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
    Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK.
    J Clin Oncol.
    2011 Jun 1
    29(16):2259-65
  12. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors
    Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, Levenson V
    Gynecol Oncol
    2011 Jan
    120(1):113-20
  13. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
    Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J.
    Int J Gynecol Cancer.
    2010 Oct
    20(7):1137-41.
  14. Helical Tomotherapy Delivery of an IMRT Boost in Lieu of Interstitial Brachytherapy in the Setting of Gynecologic Malignancy: Feasibility and Dosimetric Comparison
    Gielda BT, Shah AP, Marsh JC, Smart JP, Bernard D, Rotmensch J, Griem KL
    Med Dosim
    2010 May 25
  15. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study
    Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS
    Gynecol Oncol
    2010 Mar
    116(3):332-4
  16. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study
    Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS
    Gynecol Oncol
    2010 Dec 13
  17. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study
    Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D
    J Clin Oncol
    2009 Nov 10
    27(32):5337-42
  18. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group
    Gynecol Oncol
    2009 Nov
    115(2):215-20
  19. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer
    Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL
    Int J Gynecol Cancer
    2009 May
    19(4):531-9
  20. A dosimetric comparison of Xoft Axxent Electronic Brachytherapy and iridium-192 high-dose-rate brachytherapy in the treatment of endometrial cancer
    Dickler A, Kirk MC, Coon A, Bernard D, Zusag T, Rotmensch J, Wazer DE
    Brachytherapy
    2008 Oct-Dec
    7(4):351-4

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612